Drug Combination Details
| General Information of the Combination (ID: C25069) | |||||
|---|---|---|---|---|---|
| Name | Artesunate NP Info | + | Tafenoquine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Babesiosis
[ICD-11: 1F52]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Increase | Rapid clearance of B. microti | ||||
| In-vitro Model | Babesia bovis | Microorganism model | Babesia bovis | |||
| In-vivo Model | 8-9-weeks-old BALB/c female mice were used in this study. | |||||
| Experimental
Result(s) |
Tafenoquine (10 mg/kg, base), combined or not with artesunate, but not mefloquine, induced rapid clearance of B. microti in vivo by microscopy, but mice remained PCR-positive. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo. Parasit Vectors. 2020 Jul 20;13(1):362. | |||
